Need for additional pain relief (4 to 8 hours) · women with perineal pain in the early postpartum period
It is very uncertain whether aspirin changes need for additional pain relief (4 to 8 hours) compared with placebo (very low certainty).
1 finding from 1 review
Maternal adverse events · women with perineal pain in the early postpartum period
It is very uncertain whether aspirin changes maternal adverse effects (4 to 8 hours) compared with placebo (very low certainty).
1 finding from 1 review
Neonatal drug adverse effects · women with perineal pain in the early postpartum period
1 finding from 1 review
Early treatment failure · children and adults
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Early treatment failure · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
Has died · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus
1 finding from 1 review
Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus
1 finding from 1 review
Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus
1 finding from 1 review
Intervention not reported
Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus
1 finding from 1 review
Intervention not reported
Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus
1 finding from 1 review
Intervention not reported
Early postoperative non‐thrombotic complications · Individuals with peripheral arterial disease
The intervention showed no clear difference in early postoperative non‐thrombotic complications (high certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether colchicine changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether insulin plus glucagon changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found